Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
RARE Catalyst Timeline
Dated clinical, regulatory and corporate events for Ultragenyx Pharmaceutical Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Ultragenyx Pharmaceutical Inc.
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How RARE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-11-03 | UX701 (rivunatpagene miziparvovec) | Phase 1/2 data readout | Phase 1/2 |
Drug Pipeline Intelligence
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Crysvita | |||
| Dojolvi | |||
| Evkeeza | |||
| Mepsevii |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| setrusumab BiologicsNCT06636071 | Osteogenesis Imperfecta | Phase 3 | ACTIVE NOT_RECRUITING | 258 | Jan 1, 2028 | ||||||
| UX016 Small MoleculesNCT07511556 | GNE Myopathy | Phase 1/2 | RECRUITING | 24 | Dec 1, 2028 | ||||||
| UX111 Gene TherapiesMarketedNCT02716246 | MPS IIIA | Approved | RECRUITING | 36 | Mar 1, 2029 | ||||||
| DTX301 Gene TherapiesNCT05345171 | OTC Deficiency | Phase 3 | ACTIVE NOT_RECRUITING | 37 | Mar 1, 2031 | ||||||
| Triheptanoin Small MoleculesMarketedNCT05933200 | Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) | Approved | ACTIVE NOT_RECRUITING | 69 | Aug 1, 2027 | ||||||
| UX701 Gene TherapiesNCT04884815 | Wilson Disease | Phase 1/2 | ACTIVE NOT_RECRUITING | 82 | Mar 1, 2034 | ||||||
| GTX-102 RNA-Based TherapiesCompletedNCT04259281 | Angelman Syndrome | Phase 1/2 | COMPLETED | 74 | Jan 8, 2025 | ||||||
| setrusumab BiologicsCompletedNCT03118570 | Osteogenesis Imperfecta, Type I | Phase 2 | COMPLETED | 112 | Nov 12, 2020 | ||||||
| BPS804 BiologicsCompletedNCT01417091 | Osteogenesis Imperfecta | Phase 2 | COMPLETED | 10 | Dec 1, 2012 | ||||||
| DTX401 Gene TherapiesMarketedNCT05139316 | Glycogen Storage Disease Type IA | Approved | COMPLETED | 52 | Feb 20, 2026 | ||||||
| Burosumab BiologicsMarketedNCT03581591 | Hypophosphatemia | Approved | COMPLETED | 1 | Dec 6, 2019 | ||||||
| Evinacumab BiologicsMarketedNCT05611528 | Homozygous Familial Hypercholesterolemia | Approved | COMPLETED | 10 | Mar 18, 2025 | ||||||
| UX003 Small MoleculesMarketedNCT02230566 | MPS 7 | Approved | COMPLETED | 12 | May 1, 2016 | ||||||
| UX003 Small MoleculesMarketedNCT02418455 | Sly Syndrome | Approved | COMPLETED | 20 | Mar 26, 2019 | ||||||
| scAAV8OTC Gene TherapiesCompletedNCT02991144 | Ornithine Transcarbamylase (OTC) Deficiency | Phase 1/2 | COMPLETED | 16 | Dec 16, 2021 | ||||||
| DTX401 Gene TherapiesNot countedNCT03517085 | GSD1 | Phase 1/2 | COMPLETED | 12 | Nov 2, 2021 | ||||||
| UX003 Small MoleculesMarketedNCT01856218 | Mucopolysaccharidosis Type 7 | Approved | COMPLETED | 3 | Jul 1, 2016 | ||||||
| UX007 Small MoleculesNot countedNCT01993186 | Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | Phase 2 | COMPLETED | 36 | Sep 20, 2017 | ||||||
| UX007 Small MoleculesMarketedNCT01886378 | Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) | Approved | COMPLETED | 29 | Aug 25, 2016 | ||||||
| UX007 Small MoleculesNot countedNCT02214160 | Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency | Phase 2 | COMPLETED | 94 | Dec 3, 2020 | ||||||
| Triheptanoin Small MoleculesNot countedNCT00947960 | Adult Polyglucosan Body Disease | Phase 2 | COMPLETED | 23 | Jul 1, 2015 | ||||||
| Triheptanoin Small MoleculesNot countedNCT02432768 | Glycogen Storage Disease Type V | Phase 2 | COMPLETED | 22 | Feb 1, 2019 | ||||||
| Triheptanoin Small MoleculesNot countedNCT03642860 | Tarui Disease | Phase 2 | COMPLETED | 3 | Aug 28, 2019 | ||||||
| Triheptanoin Small MoleculesNot countedNCT02036853 | Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS) | Phase 2 | COMPLETED | 20 | Jun 30, 2019 | ||||||
| Triheptanoin Small MoleculesNot countedNCT03506425 | ALS | Phase 1/2 | COMPLETED | 15 | Mar 28, 2019 |
Clinical Trial Results
Readouts, endpoints and source filings for every RARE program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Osteogenesis Imperfecta | Phase 3 | 2026-03-30 | statistically significant reduction in annualized fracture rateRead More | RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law FirmRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Horn HowardOfficer (Chief Financial Officer) | Sell | -7,066 89,229 held | $15.27 | 10/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RARE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 1.3 % (-40.9 %) | 128.20 M | 8.53 M | 9.39% ( 732.50 K) |
Ownership Trends
RARE Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How RARE ranks across every disease it competes in
RARE News
Ultragenyx to Participate at Investor Conferences in London
Ultragenyx Pharmaceutical Inc. will participate in two investor conferences in November 2026. The UBS Global Biopharma Conference is scheduled for November 16, followed by the Jefferies Global Healthcare Conference on November 17. The leadership team will engage in fireside chats and one-on-one meetings with investors.
Read more →Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)
Ultragenyx announced that the UK MHRA accepted its Marketing Authorisation Application for rebisufligene etisparvovec (UX111) on October 28, 2026. The therapy targets Sanfilippo syndrome Type A, an ultra-rare genetic disorder. This acceptance initiates a formal scientific review of the investigational gene therapy. The company is aligning NICE evaluation with the MHRA review for potential NHS access.
Read more →Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027
Ultragenyx reported third quarter 2026 revenues of $173 million, driven by CRYSVITA and DOJOLVI sales. The company announced significant expense reductions and reaffirmed its guidance for profitability in 2027. Two BLAs for gene therapies received FDA approval, with Priority Review Vouchers expected to generate substantial revenue. However, a net loss of $118 million was reported for the quarter.
Read more →Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update
Ultragenyx Pharmaceutical Inc. will host a conference call on November 3, 2026, at 5:00 p.m. ET to discuss its financial results for Q3 2026. The call will be accessible via the company's website, with a replay available for three months. The company focuses on developing therapies for rare genetic diseases.
Read more →Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million
Ultragenyx Pharmaceutical Inc. has announced a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for $203 million. This sale follows a recent PRV transaction and aims to provide non-dilutive funding to support the company's innovative treatments for rare diseases. The transaction is subject to customary closing conditions, including regulatory reviews.
Read more →Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
Ultragenyx Pharmaceutical Inc. has announced a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for $210 million. This voucher was awarded following the FDA approval of GENGLYCOS, a treatment for glycogen storage disease type Ia. The funds will aid in advancing therapies for rare diseases, although the transaction is subject to customary closing conditions.
Read more →Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)
Ultragenyx announced the validation of its Marketing Authorisation Application for rebisufligene etisparvovec, an investigational gene therapy for MPS IIIA. This validation allows the EMA to begin a formal review, although it does not guarantee approval. The therapy aims to address a significant unmet medical need in a rare disease community.
Read more →Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)
Ultragenyx Pharmaceutical Inc. announced that the FDA has granted full approval for FAYUVI™, the first-ever treatment for Sanfilippo syndrome Type A. This gene therapy aims to halt the disease's progression and will be available to Qualified Treatment Centers within 30-60 days. The approval is a significant milestone for the affected community, offering hope to families facing this devastating condition.
Read more →Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome
Ultragenyx announced that its Phase 3 Aspire study for apazunersen in Angelman syndrome failed to meet its primary and secondary endpoints. The results have led to disappointment from the company and the patient community. The company will evaluate the program's future and implement expense reductions while focusing on its commercial business.
Read more →Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic Disease
Ultragenyx announced that GENGLYCOS reduced daily cornstarch intake by 61% in a 96-week trial for GSDIa. The therapy maintained glycemic control while allowing 33% to 42% of patients to eliminate nighttime dosing. These results were published in The Journal of Inherited Metabolic Disease. The drug received FDA approval for patients aged eight and older.
Read more →Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical Inc. has granted 45,984 restricted stock units to 23 newly hired non-executive officers as part of its Employment Inducement Plan. This grant, approved by the compensation committee, aims to attract talent in line with Nasdaq Listing Rule 5635(c)(4). The stock units will vest over four years, contingent on continued employment.
Read more →Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)
The U.S. Food and Drug Administration granted accelerated approval for GENGLYCOS, a gene therapy for glycogen storage disease type Ia. This marks Ultragenyx’s first gene therapy approval and fifth overall regulatory clearance. The decision follows Phase 3 data showing reduced cornstarch requirements in 46 participants. Ultragenyx will receive a Priority Review Voucher as part of the approval process.
Read more →Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update
Ultragenyx reported second quarter total revenue of $214 million, driven by $156 million from Crysvita and $27 million from Dojolvi. The company reaffirmed its full year 2026 revenue guidance of $730 million to $760 million. It also maintained its outlook for combined research and development plus selling, general, and administrative expenses to remain flat to slightly down compared to 2025 levels.
Read more →Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update
Ultragenyx Pharmaceutical Inc. will host a conference call on August 4, 2026, at 5:00 p.m. ET to discuss its financial results for Q2 2026. The call will provide a corporate update and will be available for replay on the company's website for three months. Ultragenyx is dedicated to developing therapies for rare genetic diseases.
Read more →Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact
Ultragenyx Pharmaceutical Inc. released its 2025 Impact Report, highlighting its commitment to rare disease patients and innovation. The report details advancements in five investigational therapies and ongoing support for patients lacking access to approved treatments. Key achievements include significant investments in R&D and participation in global advocacy events, reflecting the company's dedication to improving patient outcomes.
Read more →Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference
Ultragenyx Pharmaceutical Inc. will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. CEO Emil Kakkis will engage in a fireside chat, which will be available via live and archived webcast. The company focuses on developing therapies for rare genetic diseases and has a strong commitment to efficient drug development.
Read more →Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference
Ultragenyx Pharmaceutical Inc. will participate in Bank of America's 2026 Healthcare Conference on May 12, 2026. CFO Howard Horn and Chief of Staff Joshua Higa will lead a fireside chat, which will be accessible via webcast. The company focuses on developing therapies for rare genetic diseases and aims to address high unmet medical needs.
Read more →